123 related articles for article (PubMed ID: 15028258)
1. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
3. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
[TBL] [Abstract][Full Text] [Related]
5. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
6. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
Smets LA; Loesberg C; Janssen M; Metwally EA; Huiskamp R
Cancer Res; 1989 Jun; 49(11):2941-4. PubMed ID: 2720653
[TBL] [Abstract][Full Text] [Related]
7. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
8. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.
Buck J; Bruchelt G; Girgert R; Treuner J; Niethammer D
Cancer Res; 1985 Dec; 45(12 Pt 1):6366-70. PubMed ID: 3864530
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
10. Meta-iodobenzylguanidine and analogues: chemistry and biology.
Vaidyanathan G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
[TBL] [Abstract][Full Text] [Related]
11. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
13. Sympathomimetic effects of MIBG: comparison with tyramine.
Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
[TBL] [Abstract][Full Text] [Related]
14. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
15. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
16. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
17. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).
Kuin A; Rutgers M; van der Valk MA; Beijnen JH; Smets LA
Br J Cancer; 1999 Feb; 79(5-6):802-6. PubMed ID: 10070872
[TBL] [Abstract][Full Text] [Related]
19. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR
Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223
[TBL] [Abstract][Full Text] [Related]
20. Potential and practical adrenomedullary PET radiopharmaceuticals as an alternative to m-iodobenzylguanidine: m-(omega-[18F]fluoroalkyl)benzylguanidines.
Lee BC; Paik JY; Chi DY; Lee KH; Choe YS
Bioconjug Chem; 2004; 15(1):104-11. PubMed ID: 14733589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]